Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Sep-Oct;26(5):386-93.
doi: 10.5993/ajhb.26.5.7.

A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation

Elbert D Glover  1 , Penny N Glover, C Rollynn Sullivan, Connie L Cerullo, Gerald Hobbs
Affiliations
Clinical Trial

A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation

Elbert D Glover et al. Am J Health Behav. 2002 Sep-Oct.

Abstract

Objective: To evaluate the potential efficacy of bupropion sustained release when used in combination with minimal counseling for moist snuff cessation in males.

Methods: A double-blind, placebo-controlled 3-month trial. The active treatment group (n = 35) received bupropion SR at 150 mg/qd day for the first 3 days, then beginning day 4 through day 49 (7 weeks) 150 mg/ b.i.d. The placebo group (n= 35) received 1 tablet qd for 3 days and beginning day 4 through day 49, 1 tablet/b.i.d.

Results: Bupropion 300 mg/day (150 b.i.d.) produced significantly higher quit rates for smokeless tobacco cessation at the end of treatment (7 weeks) than placebo (p = 0.04) with an OR of 2.73.

Conclusion: Bupropion SR appears to be effective for smokeless tobacco cessation.

PubMed Disclaimer

Publication types

LinkOut - more resources